Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Alzheimer’s

Adlarity (donepezil hydrochloride) transdermal system

Approval Date: Mar 2022

Note: New Product

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

ADUHELM (ADUCANUMAB-AVWA) INJECTION

Approval Date: Jun 2021

Note: New Product

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

Medication Name

Approval Date

Category

Description

Adlarity (donepezil hydrochloride) transdermal system

Mar 2022

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

Note: New Product

ADUHELM (ADUCANUMAB-AVWA) INJECTION

Jun 2021

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

Note: New Product
lockenvelopephone-handsetmenucross-circle